EUCTR2020-001390-76-IT进行中（未招募）1 期
A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients with severe COVID-19 pneumonia - ESCAPE
ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI0 个研究点目标入组 171 人开始时间: 2020年6月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 171
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age = 18 years
- •2.Signed informed consent provided by the patient, or by the patient’s legally authorized representative(s), as applicable. Orally provisions could be considered in emergency conditions if deemed necessary by the investigator (signature of the informed consent will occur if and as soon as clinical conditions improve).
- •3.Virological diagnosis of SARS-CoV-2 infection (SARS-CoV-2 infection confirmed by PCR test or positive serology)
- •4.Evidence of pulmonary infiltrates at CT scan or Chest XRay
- •5.Oxygen saturation (SpO2) at rest without oxygen supplementation < 93% or PaO2/FiO2 < 300 at rest in patients requiring oxygen supplementation (either Venturi mask or cPAP or NIV).
- •6.Evidence of hyperinflammation defined as at least two of the following:
- •i.Blood lymphocytes <1000/mm3
- •ii. Ferritin > 500ng/mL;
- •iii.LDH > 300 U/L;
- •iv.D-Dimers > 1000 ng/mL
- •v.C-reactive protein > 3 mg/dL
- •7.Indication to start antiviral therapy with either hydroxychloroquine or lopinavir/ritonavir as regular clinical practice (or patients who have already started/finished antiviral therapy for SARS-CoV2)
- •8.Men and women of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception as described in Appendix F.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 71
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1.Known hypersensitivity to sarilumab or its excipients
- •2.Known active infections or other clinical condition that contraindicate sarilumab and cannot be treated or solved according to the judgement of the clinician
- •3.Patient being treated with immunomodulators or anti-rejection drugs
- •4.Pregnancy/lactation
- •5.Neutrophils count < 500 cell/mm3
- •6.Platelets count < 50.000/mm3
- •7.ALT / AST> 5 times the upper limit of the normality
- •8.Bowel diverticulitis or perforation
- •9.Existence of any life-threatening co-morbidity or any other medical condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion.
- •10.Severe hepatic dysfunction
- •11.Creatinine clearance < 30 ml/min/1.73 m2
- •12.Mechanical ventilation or ECMO
- •13.Enrolment in another concurrent clinical interventional study
- •14.Intake of an investigational drug within 3 months
研究者
相似试验
已完成
3 期
A Phase III study to evaluate the immunogenicity, reactogenicity and safety of ROTAVAC 5CM compared with existing ROTAVAC® in healthy infants aged 6-8 weeksCTRI/2016/11/007481Bharat Biotech International Limited360
招募中
1 期
ot applicableEUCTR2010-019952-35-ITCEL-SCI Corporation880
进行中（未招募）
1 期
A Phase III Study of the Effects of Multikine on Cancer of the Oral CavityEUCTR2010-019952-35-HRCEL-SCI Corporation1,273
进行中（未招募）
1 期
A Study with a product called Multikine used in treatment of Mouth CancerSubjects with Advanced Primary Sqamous Cell Carcinoma of the oral Cavity/Soft PalateMedDRA version: 20.0Level: LLTClassification code 10030965Term: Oral carcinoma in situSystem Organ Class: 100000004864EUCTR2010-019952-35-GBCEL-SCI Corporation880
已完成
3 期
Efficacy and Safety Study of Leukocyte Interleukin, Injection (LI) to Treat Cancer of the Oral CavitySquamous Cell Carcinoma of the Oral Cavity and soft palateSLCTR/2014/017Dr. E Talor